Misplaced Pages

This is the current revision of this page, as edited by Buidhe (talk | contribs) at 20:54, 1 December 2023 (Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot). The present address (URL) is a permanent link to this version.

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.

References

1. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. (November 2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
2. Clinical trial number NCT00000836 for "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)" at ClinicalTrials.gov

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Experimental antiviral drugs
• Antiinfective agent stubs
• Monoclonal antibody stubs